RELEVANCE : A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat.

André, Marc

RELEVANCE : A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat.

André, Marc

(2013) Belgian Journal of Hematology — Vol. 4, n° 1, p. 36-38 (2013)

Files

No attached file found for this publication.

Details

Authors

André, MarcUCLouvain
Author

Affiliations

UCLouvain(MGD) Service d'hématologie
UCLouvainSSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie

Citations

APA
Chicago
FWB

André, M. (2013). RELEVANCE : A phase 3 randomised study comparing efficacy and safety of rituximab plus lenalidomide versus rituximab plus chemotherapy in first-line patients with follicular lymphomat. Belgian Journal of Hematology, 4(1), 36-38. https://hdl.handle.net/2078.5/66659 (Original work published 2013)